Dutheuil; Guillaume

Patent Applications and Registrations

Patent applications and USPTO patent grants for Dutheuil; Guillaume.The latest application filed is for "synthesis of 3-methyl-1,2,4-thiadiazole-5-carbohydrazide or of the methyl-d3 deuterated form thereof".

Company Profile

11.18.26

Dutheuil; Guillaume - Vedrin BE
Dutheuil; Guillaume - Flenu BE

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
SYNTHESIS OF 3-METHYL-1,2,4-THIADIAZOLE-5-CARBOHYDRAZIDE OR OF THE METHYL-d3 DEUTERATED FORM THEREOF App 20220056000 - Hoveyda; Hamid ; et al.	2022-02-24
NOVEL N-ACYL-[3-SUBSTITUTED]-[8-SUBSTITUTED]-5,6-DIHYDRO-[1,2,4]TRIAZOLO[4- ,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS App 20210094959 - Hoveyda; Hamid R. ; et al.	2021-04-01
Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazi- nes as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof Grant 10,941,151 - Hoveyda , et al. March 9, 2	2021-03-09
N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]p- yrazines as selective NK-3 receptor antagonists Grant 10,836,768 - Hoveyda , et al. November 17, 2	2020-11-17
Chiral synthesis of N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-A]- pyrazines Grant 10,787,458 - Hoveyda , et al. September 29, 2	2020-09-29
Novel Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines As Selective Nk-3 Receptor Antagonists, Phar App 20200283447 - Hoveyda; Hamid R. ; et al.	2020-09-10
Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-A]pyrazi- nes as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof Grant 10,683,295 - Hoveyda , et al.	2020-06-16
Novel Nk-3 Receptor Selective Antagonist Compounds, Pharmaceutical Composition And Methods For Use In Nk-3 Receptors Mediated Di App 20200125564 - Hoveyda; Hamid R. ; et al.	2020-04-23
NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders Grant 10,544,150 - Hoveyda , et al. Ja	2020-01-28
Novel Chiral Synthesis Of N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]- Pyrazines App 20190218225 - HOVEYDA; Hamid ; et al.	2019-07-18
NOVEL N-ACYL-(3-SUBSTITUTED)-(8-SUBSTITUTED)-5,6-DIHYDRO-[1,2,4]TRIAZOLO[4- ,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS App 20190092777 - HOVEYDA; Hamid ; et al.	2019-03-28
N-acyl-(3-substituted)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders Grant 10,214,533 - Hoveyda , et al. Feb	2019-02-26
Novel Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines As Selective Nk-3 Receptor Antagonists, Pharmaceutical Composition, Methods For Use In Nk-3 Receptor Mediated Disorders And Chiral Synthesis Thereof App 20190023711 - Hoveyda; Hamid R. ; et al.	2019-01-24
N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]p- yrazines as selective NK-3 receptor antagonists Grant 10,183,948 - Hoveyda , et al. Ja	2019-01-22
NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders Grant 10,065,960 - Hoveyda , et al. September 4, 2	2018-09-04
Chiral N-acyl-5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyraz- ines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof Grant 10,065,961 - Hoveyda , et al. September 4, 2	2018-09-04
NOVEL N-ACYL-(3-SUBSTITUTED)-5,6,7,8-TETRAHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRA- ZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS App 20180237446 - HOVEYDA; Hamid ; et al.	2018-08-23
Substituted [1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists Grant 10,030,025 - Hoveyda , et al. July 24, 2	2018-07-24
Novel Nk-3 Receptor Selective Antagonist Compounds, Pharmaceutical Composition And Methods For Use In Nk-3 Receptors Mediated Disorders App 20180194772 - Hoveyda; Hamid R. ; et al.	2018-07-12
N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]p- yrazines as selective NK-3 receptor antagonists Grant 9,987,274 - Hoveyda , et al. June 5, 2	2018-06-05
N-acyl-(3-substituted)-(8-methyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazi- nes as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders Grant 9,969,745 - Hoveyda , et al. May 15, 2	2018-05-15
N-acyl-(3-substituted)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders Grant 9,969,738 - Hoveyda , et al. May 15, 2	2018-05-15
NOVEL N-ACYL-(3-SUBSTITUTED)-(8-SUBSTITUTED)-5,6-DIHYDRO-[1,2,4]TRIAZOLO[4- ,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS App 20180111943 - HOVEYDA; Hamid ; et al.	2018-04-26
NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders Grant 9,926,325 - Hoveyda , et al. March 27, 2	2018-03-27
NOVEL N-ACYL-(3-SUBSTITUTED)-(8-METHYL)-5,6-DIHYDRO-[1,2,4]TRIAZOLO[4,3-a]- PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS App 20180065972 - HOVEYDA; Hamid ; et al.	2018-03-08
N-acyl-(3-substituted)-(8-methyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a] pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders Grant 9,840,508 - Hoveyda , et al. December 12, 2	2017-12-12
Novel Chiral Synthesis Of N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]- Pyrazines App 20170298070 - HOVEYDA; Hamid ; et al.	2017-10-19
SUBSTITUTED [1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS App 20170240551 - HOVEYDA; Hamid ; et al.	2017-08-24
NOVEL N-ACYL-(3-SUBSTITUTED)-(8-SUBSTITUTED)-5,6-DIHYDRO-[1,2,4]TRIAZOLO[4- ,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS App 20170095472 - HOVEYDA; Hamid ; et al.	2017-04-06
NOVEL CHIRAL N-ACYL-5,6,7,(8-SUBSTITUTED)-TETRAHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR MEDIATED DISORDERS AND CHIRAL SYNTHESIS THEREOF App 20170029429 - Hoveyda; Hamid ; et al.	2017-02-02
SUBSTITUTED [1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS App 20160318941 - HOVEYDA; Hamid ; et al.	2016-11-03
Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazi- nes as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof Grant 9,475,814 - Hoveyda , et al. October 25, 2	2016-10-25
NOVEL N-ACYL-(3-SUBSTITUTED)-5,6,7,8-TETRAHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRA- ZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS App 20160304521 - HOVEYDA; Hamid ; et al.	2016-10-20
NOVEL N-ACYL-(3-SUBSTITUTED)-(8-METHYL)-5,6-DIHYDRO-[1,2,4]TRIAZOLO[4,3-a] PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS App 20160289233 - HOVEYDA; Hamid ; et al.	2016-10-06
Substituted [1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists Grant 9,422,299 - Hoveyda , et al. August 23, 2	2016-08-23
Novel Nk-3 Receptor Selective Antagonist Compounds, Pharmaceutical Composition And Methods For Use In Nk-3 Receptors Mediated Disorders App 20150315199 - Hoveyda; Hamid R. ; et al.	2015-11-05
NOVEL N-ACYL-(3-SUBSTITUTED)-(8-SUBSTITUTED)-5,6-DIHYDRO-[1,2,4]TRIAZOLO[4- ,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS App 20150232471 - HOVEYDA; Hamid ; et al.	2015-08-20
Novel Nk-3 Receptor Selective Antagonist Compounds, Pharmaceutical Composition And Methods For Use In Nk-3 Receptors Mediated Disorders App 20140371218 - Hoveyda; Hamid R. ; et al.	2014-12-18
NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders Grant 8,871,761 - Hoveyda , et al. October 28, 2	2014-10-28
NOVEL CHIRAL N-ACYL-5,6,7(8-SUBSTITUTED)-TETRAHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR MEDIATED DISORDERS AND CHIRAL SYNTHESIS THEREOF App 20140275097 - Hoveyda; Hamid R. ; et al.	2014-09-18
Novel Nk-3 Receptor Selective Antagonist Compounds, Pharmaceutical Composition And Methods For Use In Nk-3 Receptors Mediated Disorders App 20130023530 - Hoveyda; Hamid R. ; et al.	2013-01-24
Compounds, Pharmaceutical Composition And Methods For Use In Treating Metabolic Disorders App 20110230477 - Hoveyda; Hamid ; et al.	2011-09-22
Novel Piperidine-4-Acetic Acid Derivatives and Their Use App 20090048291 - Huck; Jacques ; et al.	2009-02-19

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.